Dutch clinical-stage drug developer NewAmsterdam Pharma saw its shares close up 41% at $26.19 yesterday on positive research ...
NewAmsterdam Pharma said Tuesday its cholesterol drug lowered the risk of major cardiovascular events and the biotech stock ...
The findings add to evidence that the company’s drug, obicetrapib, could change the narrative surrounding a once-abandoned ...
Jefferies, Goldman Sachs & Co., Leerink Partners, TD Cowen, Guggenheim Securities and William Blair are acting as joint book-running managers for the proposed Offering.
Company announced the commencement of an underwritten public offering of $300M of the company’s ordinary shares, ...
NewAmsterdam Pharma (Nasdaq: NAMS) took a commanding leap in the stock market, thanks to the announcement of positive topline data from its Phase 3 BROADWAY clinical trial. This trial evaluated ...
NewAmsterdam Pharma reports Phase 3 trial success for obicetrapib, achieving significant LDL-C reduction in ASCVD and HeFH ...
NewAmsterdam is singing data from its Broadway heart disease trial, hailing another phase 3 win for its cholesterol-busting ...
During the last three months, 5 analysts shared their evaluations of NewAmsterdam Pharma NAMS, revealing diverse outlooks ...
NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) has earned an average recommendation of “Buy” from the six research firms ...
Check the time stamp on this data. Updated AI-Generated Signals for Newamsterdam Pharma Company N.v. Warrant (NAMSW) ...
Investor's Business Daily on MSN13h
NewAmsterdam Pharma Soars 41% On An Surprise Benefit From Cholesterol DrugNewAmsterdam Pharma said Tuesday its cholesterol drug lowered the risk of major cardiovascular events and the biotech stock ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback